Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-specific T cells (University Hospital, Ghent)
- Development stage
- Phase 2
- Lead developer
- Ghent University Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CMV-specific T cells developed by University Hospital, Ghent, are an adoptive cellular immunotherapy designed to treat relapsing or refractory cytomegalovirus (CMV) infections in patients following allogeneic stem cell transplantation (SCT). The therapy involves the ex vivo isolation of CMV-specific T cells from a CMV-seropositive donor. These cells are selected based on their secretion of interferon-gamma (IFN-γ) after stimulation with the CMV immunodominant protein pp65. This process yields a mixture of both CD4+ helper and CD8+ cytotoxic T cells, which are then infused into the patient to restore protective antiviral immunity. This approach aims to overcome the limitations of standard antiviral drugs and the high mortality associated with refractory CMV disease in immunocompromised post-SCT patients by providing a sustained, donor-derived immune response against the virus.
- Other names
- pp65-specific T cellspp-65-specific T cellspp 65-specific T cellsCMV-specific cytotoxic T lymphocytesCMV-CTLsCMV-specific T-cell therapy
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on CMV-specific T cells (University Hospital, Ghent).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-specific T cells (University Hospital, Ghent).